Methods and compositions comprising a cardio-tolerated HDAC inhibitor
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- HUYA BIOSCIENCE INTERNATIONAL LLC
- Filing Date
- 2026-05-06
- Publication Date
- 2026-07-10
Smart Images
Figure 00000000_0000_ABST
Abstract
Description
Abstract This article provides methods comprising HDAC inhibitors (HDACi), PD-L1 inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, and / or anticancer agents. Furthermore, this article also provides pharmaceutical compositions suitable for cancer treatment.
Claims
ES Docket No.: 94919-0785.745601WO CLAIMS WHAT IS CLAIMED IS:
1. A method of treating a subject with an HDAC inhibitor (HDACi), comprising administering to the subject an effective amount of an HDACi that causes no increase in QTc, QTcF, or heart rate (HR).
2. The method of claim 1, wherein said administering of HDACi causes a decrease in QTc, QTcF, or HR in the subject.
3. The method of claim 1 or claim 2, wherein administering the HDACi to subject at increasing dosage results in reduced QTcF.
4. The method of any of claims 1-3, wherein administering the HDACi to the subject results in no change in HR or a decrease in HR.
5. The method of any of claims 1-4, wherein the HDACi inhibits class I and class IIb HDACs.
6. The method of claim 5, wherein the HDACi inhibits one or more of HDAC1, HDAC2, HDAC3, or HDAC10.
7. The method of claim 6, wherein the HDACi inhibits all of HDAC1, HDAC2, HDAC3, and HDAC10.
8. The method of any of claims 1-7, wherein the HDACi is tucidinostat (chidamide).
9. The method of any of claims 1-8, wherein the effective amount is an amount effective to treat cancer.
10. The method of any one of claims 1-9, wherein the cancer is an advanced solid tumor or hematological cancer.
11. The method of claim 10, wherein the cancer is one or more of melanoma, renal cell carcinoma, or non-small cell lung cancer (NSCLC).
12. The method of any of claims 1-11, wherein the effective amount is about 5 mg to about 80 mg per day.ES Docket No.: 94919-0785.745601WO 13. The method of claim 12, wherein the HDACi is administered as an oral dose.
14. The method of claim 13, wherein the HDACi is administered at a dose of about 20 mg, about 30 mg, or about 40 mg once daily during a cycle.
15. The method of claim 14, wherein the cycle is at least about two days in duration.
16. The method of claim 15, wherein the cycle is from about one week to about ten weeks in duration.
17. The method of claim 16, further comprising administering an anti-cancer agent, PD-1 inhibitor or a PD-L1 inhibitor.
18. The method of claim 17, wherein the PD-1 inhibitor or PD-L1 inhibitor is administered on day 2 of the cycle.
19. The method of claim 18, wherein the PD-1 inhibitor is an anti-PD-1 antibody.
20. The method of claim 19, wherein the anti-PD-1 antibody is nivolumab.
21. The method of claim 20, wherein nivolumab is administered to the subject at a dose of 240 mg per administration every two (2) weeks.